



Biotech Daily

Monday November 30, 2015

Daily news on ASX-listed biotechnology companies

- * **ASX DOWN, BIOTECH EVEN: COMPUMEDICS UP 17%; OPTISCAN DOWN 25%**
- * **ANTEO DIASOURCE \$12m RIGHTS ISSUE, \$15m CONVERTIBLE NOTE**
- * **EURO PATENT FOR NEUREN'S NNZ-2591 FOR PARKINSON'S, AUTISM**
- * **3D TO DISTRIBUTE CLIENT OUTLOOK'S EUNITY IMAGING PRODUCTS**
- * **CIRCADIAN NEW DIRECTORS TRADING HALT, NAME CHANGE AGM**
- * **OPTISCAN 41% OPPOSE CFO, DIRECTOR BRUCE ANDREW**
- * **PRESCIENT APPOINTS PROF JEFFREY LANCET ADVISOR**

MARKET REPORT

The Australian stock market fell 0.69 percent on Monday November 30, 2015 with the ASX200 down 36.1 points to 5,166.5 points.

Fourteen of the Biotech Daily Top 40 stocks were up, 14 fell, eight traded unchanged and four were untraded. All three Big Caps rose.

Compumedics was the best, up 7.5 cents or 17.2 percent to 51 cents with 946,939 shares traded, followed by Neuren up 10 percent to 9.9 cents with 1.9 million shares traded.

Genetic Technologies climbed 9.7 percent; IDT, Impedimed and Viralytics improved more than four percent; Polynovo was up 3.2 percent; both Bionomics and Medical Developments rose 2.1 percent; Admedus, Benitec, Resmed, Sirtex and Starpharma were up one percent or more; with Cochlear, CSL and Nanosonics up by less than one percent.

Optiscan led the falls, down 0.9 cents or 25 percent to 2.7 cents with 774,432 shares traded, followed by Orthocell down 14.9 percent to 40 cents with 766,778 shares traded.

Anteo and Ellex lost more than nine percent; Osprey fell 6.25 percent; Atcor was down 5.7 percent; Actinogen, Cellmid and Prana were down three percent or more; Pharmaxis and Universal Biosensors shed more than two percent; Clinuvel and Mesoblast were down more than one percent; with Pro Medicus down 0.3 percent.

ANTEO DIAGNOSTICS

Anteo says it is in the final stages of securing funding for the acquisition of Diasource including a \$12 million rights issue at 7.5 cents and a \$14.7 million convertible note. In August, Anteo said it would acquire the Belgium-based Diasource Immunoassays SA for up to EUR22.7 million (\$A34.4 million) with a share plan for an initial payment of EUR15.4 million (\$A23.3 million) in cash and/or shares at completion of the acquisition, with an earn-out component up to EUR7.3 million (\$A11.1 million), subject to revenue and margin targets, with a minimum 20 percent in shares, subject to financing, regulatory approvals and other conditions (BD: Aug 26, 2015).

The company said at that time the Diasource headquarters near Brussels, combined offices and laboratories with a manufacturing and storage facility, providing diagnostics products for endocrinology, fertility, cardiovascular and oncology to customers in 75 countries, through a network of 90 main distributors and 40 "original equipment manufacturers" generating revenue of \$18.0 million in 2014.

Today, Anteo said that along with the one-for-5.36 non-renounceable rights issue at 7.5 cents to raise up to \$12,018,427 for shareholders at the record date of December 4, 2015, it had a conditional heads of agreement for a EUR10 million (\$A14.7 million) convertible note with an unnamed Toronto-based institutional investor, and a potential placement to institutional and sophisticated investors after completion of the entitlement issue.

The company said it had a conditional underwriting from PAC Partners for any shortfall in the rights issue subject to sub-underwriting, including chief executive officer Dr Geoff Cumming and chief financial officer Richard Martin for up to \$900,000, collectively.

Anteo said the four-year, 10 percent per annum convertible note could be converted at any time by the note-holder, with a minimum price of 15 cents a share in tranches of EUR500,000 but if the conditions were not satisfied or waived by the note-holder, and in the absence of alternate funding, and despite the raising of funds it might not be in a position to complete the acquisition of Diasource.

Anteo said that the acquisition was expected to be completed by December 31, 2015.

Anteo fell 0.8 cents or 9.3 percent to 7.8 cents with 2.7 million shares traded.

NEUREN PHARMACEUTICALS

Neuren says the European Patent Office has granted a patent covering the composition of drug candidate NNZ-2591.

Neuren said the patent, entitled 'Neuroprotective Bicyclic Compounds and Methods for their Use' provided coverage to August 2024, with the potential to extend protection in the European Union for up to five years through supplementary protection certificates.

The company said that similar patents covering the composition of NNZ-2591 had been issued in the US and Japan and three additional patents had been issued in the US, covering methods for treating Parkinson's disease, peripheral neuropathy and cognitive impairment, with an international application pending covering methods for treating autism spectrum disorders and neurodevelopmental disorders.

The company said that NNZ-2591 was a "dipeptide with excellent oral bioavailability and potential for improved stability compared with other peptide-like compounds".

Neuren said that NNZ-2591 exhibited "potent neuro-protective, neuro-restorative and pro-cognitive effects", resulting from inhibition of inflammation and cell death as well as normalization of synaptic plasticity and neuronal signaling.

The company said that NNZ-2591 had shown efficacy in pre-clinical models of Parkinson's disease, stroke, traumatic brain injury, peripheral neuropathy, Fragile X syndrome, memory impairment and multiple sclerosis.

Neuren was up 0.9 cents or 10 percent to 9.9 cents with 1.9 million shares traded.

3D MEDICAL

3D Medical says it has a five-year reseller agreement with Waterloo, Ontario-based Client Outlook to distribute its Eunity medical image viewing and collaboration platform.

3D said that the distribution agreement allowed it to distribute Client Outlook's medical image software products worldwide and generate fees based on the number of radiology images examined through the software.

The company said that since 2009, the Eunity medical image viewing product had been used across hundreds of clinical sites and handled millions of medical imaging exams. 3D said that the Eunity platform provided a way to view diagnostic quality images and reports and collaborate in real-time using a web browser without the need to install specialized.

3D Medical was unchanged at 6.7 cents.

CIRCADIAN TECHNOLOGIES

Circadian requested a trading halt today pending board changes to be announced at the end of the annual general meeting, which voted on its name change to Opthea.

Biotech Daily understands that all resolutions were passed and that there has been a significant change of directors, but the announcement had not been released to the ASX at the time of publication (BD: Oct 30, 2015).

Circadian last traded at 31 cents.

OPTISCAN

Optiscan director and chief financial officer Bruce Andrew was re-elected with 29,981,748 votes (58.6%) in favour but with 21,194,382 votes (41.4%) opposed.

Optiscan said that the other three resolutions on the remuneration report, the election of director Patrick O'Connor and the ratification of convertible notes were passed overwhelmingly.

The company's most recent Appendix 3B new issue announcement said that Optiscan had 221,823,882 shares on issue, meaning that the votes against Mr Phillips amounted to 9.6 percent of the company, sufficient to requisition extraordinary general meetings. Optiscan fell 0.9 cents or 25 percent to 2.7 cents.

PRESCIENT THERAPEUTICS

Prescient says it has appointed Prof Jeffrey Lancet to its scientific advisory board.

Prescient said that Prof Lancet was a medical oncologist at the Tampa, Florida-based H Lee Moffitt Cancer Center working in the development and implementation of clinical trials using small molecule inhibitors in acute leukaemias.

The company said it expected to begin a clinical trial in acute myeloid leukaemia (AML) in 2016 and Prof Lancet was an investigator on its earlier 32-patient phase I trial at the MD Anderson and Moffitt Cancer Center, in Tampa.

Last week, Prescient appointed the Houston-based University of Texas MD Anderson leukaemia expert Prof Farhad Ravandi to the board (BD: Nov 26, 2015).

Prescient fell half a cent or 7.1 percent to 6.5 cents.